DCR-HBVS

Roche pays $200M for rights to Dicerna's hepatitis B RNAi drug
Fierce Biotech
Thu, 10/31/19 - 10:29 am
Roche
Dicerna Pharmaceuticals
RNAi
hepatitis B
DCR-HBVS